TPE3: ECONOMIC EVALUATION OF DIFFERENT STRATEGIES OF A VACCINATION AGAINST HEPATITIS A AND HEPATITIS B  by Smala, A et al.
Abstracts 375
TPE2
ECONOMIC EVALUATION OF ENOXAPARIN
AS POST DISCHARGE PROPHYLAXIS FOR 
DEEP VEIN THROMBOSIS (DVT) IN ELECTIVE 
HIP SURGERY
Davies LM1, Richardson GA1, Cohen AT2
1Centre for Health Economics, University of York, York, UK; 
2Department of Medicine, Guys, Kings, Thomas’s School of 
Medicine and Dentistry, Denmark Hill, London, UK
OBJECTIVES: Previous research suggests heparin to pre-
vent DVT following orthopaedic surgery is value for
money. Recent trials indicate that extending the duration
of prophylaxis may prevent additional DVT’s, but in-
crease the cost of prophylaxis. The objective of this study
was to compare the expected costs and benefits of using
enoxaparin (a low molecular weight heparin) for the in-
dex hospital admission only versus enoxaparin for hospi-
tal admission and 21 days post discharge.
METHODS: Decision analysis was used to combine prob-
ability, resource use and unit cost data, from the perspec-
tive of the UK NHS and patients. Expected costs and ben-
efits of standard and extended regimes were estimated for
a hypothetical cohort of 1000 patients undergoing elective
hip replacement. Three alternative measures of outcome
were used: lives gained, life years gained and quality ad-
justed life years (QALY) gained. Costs of events were esti-
mated as quantity and type of health care resources used,
multiplied by unit costs. Data for the model was based on
point estimates from a review of clinical and economic lit-
erature. Statistical techniques were not appropriate to as-
sess the level of uncertainty associated with the results.
Sensitivity analysis across minimum and maximum values
of variables was used to test the robustness of the results.
RESULTS: The expected cost per QALY for extended
enoxaparin was £3,145 (range £1268/QALY to £15212/
QALY). Extended enoxaparin was cost saving if 66% of
patients or carers could administer prophylaxis post dis-
charge.
CONCLUSIONS: Whilst conservative data were used to
bias the analysis against extended enoxaparin, limitations
in the data and modelling techniques mean that the results
of the analysis are only indicative of the potential value
for money. The results indicated extended enoxaparin
was associated with a cost/QALY of £1268–£15212,
which compares well with the cost/QALY for other health
care interventions funded by the UK NHS.
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ECONOMIC EVALUATION OF DIFFERENT 
STRATEGIES OF A VACCINATION AGAINST 
HEPATITIS A AND HEPATITIS B
Smala A1, Berger K1, Szucs T2
1MERG—Medical Economics Research Group, Munich, 
Germany; 2Universitäts Spital Zurich, Zurich, Switzerland
OBJECTIVES: To compare two combined vaccination
strategies against hepatitis A and hepatitis B (at age 1–15
years or at age 11–15 years) with non-vaccination in chil-
dren and youth, to analyse net-costs per strategy, cost-
effectiveness and epidemiologic development in projection
for the next 30 years in Germany.
METHODS: A period of 3 times 10 years is given, model-
ing present data on birth rate development, incidence and
course of disease and treatment costs per case, calculating
incidence, cases of infection resp. disease and treatment
costs, calculated from the TPP’s perspective. Costs per case
and courses were obtained retrospectively from standard-
ized interviews with pediatricians and from the literature.
Cost-effectiveness is assessed as costs per avoided hepatitis
A or hepatitis B infection for each strategy.
RESULTS: Significant drop in HAV and HAB incidence in
vaccinated age groups: Through vaccination of all 1–15
year old children, a reduction of 57 600 new HAV infec-
tions and of 45 800 new HBV infections in 30 years can
be demonstrated. In the vaccination group 11–15 years,
19 800 new infections with HAV and 21 900 new infec-
tions with HBV can be avoided. Vaccination costs over 30
years amount to 1.5 billion DM in the vaccination strategy
11–15 years and 3.7 billion DM in the vaccination strategy
1–15 years. Significant decrease in new infections saves
treatment costs of 1.6 billion DM for the vaccination at age
11–15 years and 2.8 billion DM for the vaccination at age
1–15 years. The cost-effectiveness of vaccination ranges
from costs of 90 100 DM up to savings of - 20 200 DM per
avoided infection, depending on cycle and vaccination strat-
egy. Considering unreported cases of hepatitis A and B as 5
fold of known incidence, the range of savings per avoided
infection is between - 3 300 DM and - 38 700 DM.
CONCLUSION: The initially more expensive combined
vaccine represents a cost-effective alternative to the sole
hepatitis B vaccination and also shows a more beneficial
effect from an epidemiological point of view. In Germany,
the strategy of vaccination between 11–15 years seems to
be the most cost-effective—on the other hand the vaccina-
tion of all between 1–15 years is superior considering the
epidemiological effects.
TPE4
DEVELOPMENT OF A QUALITY ASSESSMENT 
CHECKLIST FOR THE APPRAISAL OF 
ECONOMIC MODELS: A CASE-STUDY
IN OSTEOPOROSIS
Hege U1, Pang F2, Tolley K3
1Department of Health Sciences, University of York, York, 
North Yorkshire, UK; 2Centre for Health Economics, University 
of York, York, North Yorkshire, UK; 3Pfizer Central Research, 
Sandwich, Kent, UK
OBJECTIVES: Deriving data on clinical outcomes to pop-
ulate economic models requires a series of key decisions
upon the part of the economist. Ideally, to minimise the
potential for bias, the process of including data should be
systematic. The objective of this research is to construct a
quality assessment checklist for the inclusion of clinical
and epidemiological data in economic models, and fur-
